NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$40.10 -0.18 (-0.45 %)
(As of 07/18/2018 08:29 AM ET)
Previous Close$40.28
Today's Range$39.58 - $40.3250
52-Week Range$30.10 - $67.10
Volume482,754 shs
Average Volume936,429 shs
Market Capitalization$2.65 billion
P/E Ratio-8.34
Dividend YieldN/A
Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers. It is also developing PRT2761, which is in Phase 2 for allergic conjunctivitis; and PCSK9 inhibitor in pre-clinical study for hypercholesterolemia. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.35
Current Ratio7.59
Quick Ratio7.53


Trailing P/E Ratio-8.34
Forward P/E Ratio-7.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.55 million
Price / Sales117.05
Cash FlowN/A
Price / CashN/A
Book Value$5.36 per share
Price / Book7.48


EPS (Most Recent Fiscal Year)($4.81)
Net Income$-286,090,000.00
Net Margins-1,364.89%
Return on Equity-109.35%
Return on Assets-65.49%


Outstanding Shares65,820,000
Market Cap$2,651.44

The Truth About Cryptocurrencies

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.22) by $0.06. The biopharmaceutical company earned $6.64 million during the quarter, compared to the consensus estimate of $3.20 million. Portola Pharmaceuticals had a negative net margin of 1,364.89% and a negative return on equity of 109.35%. The company's revenue was up 29.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.74) EPS. View Portola Pharmaceuticals' Earnings History.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Portola Pharmaceuticals.

What price target have analysts set for PTLA?

6 brokerages have issued 12-month target prices for Portola Pharmaceuticals' shares. Their forecasts range from $46.00 to $80.00. On average, they expect Portola Pharmaceuticals' stock price to reach $62.80 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price. View Analyst Ratings for Portola Pharmaceuticals.

What is the consensus analysts' recommendation for Portola Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:
  • Mr. William Lis, CEO, Pres & Director (Age 54)
  • Ms. Mardi C. Dier, Interim Co-Pres, Exec. VP & CFO (Age 54)
  • Dr. John T. Curnutte, Interim Co-Pres & Exec. VP of R&D (Age 66)
  • Mr. Tao Fu, Chief Commercial & Bus. Officer and Exec. VP (Age 46)
  • Dr. John H. Lawrence III, M.D., Sr. VP & Chief Medical Officer (Age 60)

Has Portola Pharmaceuticals been receiving favorable news coverage?

Media stories about PTLA stock have trended positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a news sentiment score of 0.46 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.22 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.14%), Fox Run Management L.L.C. (0.04%) and Evanson Asset Management LLC (0.02%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Which major investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include Henry Ward Wolff, John T Curnutte, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Which major investors are buying Portola Pharmaceuticals stock?

PTLA stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Evanson Asset Management LLC. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $40.10.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $2.65 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]

MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  512
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.